- Home
- KNSA vs OBDC Comparison
KNSA vs OBDC Comparison
Compare KNSA & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | OBDC |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.6B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KNSA | OBDC |
|---|---|---|
| Price | $78.17 | $11.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $60.86 | $14.00 |
| AVG Volume (30 Days) | 667.7K | ★ 4.3M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 13.40% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.27 | 0.08 |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $37.48 | N/A |
| Revenue Next Year | $17.87 | N/A |
| P/E Ratio | $299.51 | ★ $141.63 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $32.89 | $10.52 |
| 52 Week High | $82.94 | $14.44 |
Technical Indicators
Market Signals| Indicator | KNSA | OBDC |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 50.84 |
| Support Level | $40.06 | $11.06 |
| Resistance Level | $82.94 | $11.34 |
| Average True Range (ATR) | 2.63 | 0.26 |
| MACD | -0.28 | -0.01 |
| Stochastic Oscillator | 66.49 | 41.63 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About OBDC Blue Owl Capital Corporation
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.